Skip to content

Ligand Pharmaceuticals LGND Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin15.3%+28.8pp-13.5%
Net margin46.4%+48.8pp-2.4%-42.1pp39.7%+56.7pp-17%-40.7pp
Returns
Return on equity13.5%+14.0pp-0.5%-8.6pp8%+12.7pp-4.7%-12.2pp
Return on invested capital4%+7.1pp-3.1%-8.0pp4.9%+1.7pp3.3%-10.6pp
Efficiency
Asset turnover0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×
Liquidity
Current ratio22.2×+13.3×8.9×-5.2×14.1×+11.5×2.7×-8.5×
Leverage
Debt-to-equity0.0×0.0×-0.1×0.1×+0.1×
Net debt / EBITDA-2.3×+2.9×-5.2×-4.9×-0.2×-0.7×0.4×+0.4×
Per Share
Book value per share$50.12+10.4%$45.40+15.0%$39.47+11.4%$35.42-27.8%
Valuation
Market capitalization$3.72B+83.8%$2.02B+62.6%$1.25B+10.3%$1.13B-56.3%
Price / earnings29.9×23.9×
Price / sales13.9×+1.8×12.1×+2.6×9.5×+3.7×5.8×-4.9×
Price / book3.7×+1.2×2.4×+0.7×1.8×-0.1×1.9×-1.3×
EV / EBITDA47.5×-108×155.1×+137×17.8×+6.0×11.8×-4.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Ligand Pharmaceuticals's profit margins?
Ligand Pharmaceuticals (LGND) runs a 91.9% gross margin and a 34.5% operating margin, with a 55.9% net margin.
Where do Ligand Pharmaceuticals's ratios come from?
Every ratio is computed from Ligand Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.